Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-11-13

Clinical Trial Update: Open-Label Extension of Voxelotor [Phase 3]

View source ↗

Summary

Open-label extension of voxelotor in sickle cell disease (Phase 3) has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxbryta (voxelotor)

Snippet

Sponsor: Pfizer | Conditions: Sickle Cell Disease | Phase 3 | Status: TERMINATED | Results posted: 2025-11-13